1 / 3

Phosphosulindac in Solid Lipid Nanoparticles Enhances Lung Cancer Treatment in Mice

This study investigates the efficacy of Phosphosulindac (OXT-328) in inhibiting human lung cancer growth in mice, particularly focusing on the enhanced delivery achieved through solid lipid nanoparticles (SLNs). The research highlights drug levels of Phosphosulindac and its metabolites across various organs following oral administration. Supplemental figures show analyses of TUNEL-positive and Ki-67-positive cells, illustrating the correlation between tumor drug concentration and cell proliferation/apoptosis markers. These findings suggest that targeted formulation enhances therapeutic outcomes in lung cancer treatment.

cally-rosales
Download Presentation

Phosphosulindac in Solid Lipid Nanoparticles Enhances Lung Cancer Treatment in Mice

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phosphosulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: Enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles Supplemental figures

  2. Suppl.Fig.1 Drug level of PS and its metabolites in four organs after treated with PS via po.

  3. TUNEL (+)% Cell Ki-67 (+)% Cell Drug level, pmole/mg protein Suppl.Fig.2 Correlation between tumor drug level and Ki-67 or TUNEL positive cell ratio.

More Related